Controlled-rate freezing and storage in vapour phase nitrogen are used by most transplantation teams for the cryopreservation and storage of peripheral blood haematopoietic stem cells (PBSC). In this study, we analysed 666 autologous PBSC transplants after uncontrolled freezing and storage of PBSC at − 80°C. Statistical analysis showed that neutrophil recovery was associated with both the infused CD34 + cell dose (P = 0.01) and the post transplantation use of growth factors (P o 0.001) and that platelet recovery was associated with the infused CD34 + cell dose (P o0.001) and with the diagnosis (P = 0.02). We analysed three groups according to the duration of the cryopreservation period (less than 6 months, between 6 and 12 months or more than 1 year). Haematopoietic recovery was not found to be adversely affected by longer storage at − 80°C. The haematopoietic recoveries of 50 pairs of sequential transplantations from the same PBSC mobilization were analysed. Despite prolonged cryopreservation, there were no statistically significant differences in neutrophil (P = 0.09) or platelet (P = 0.22) recovery in the second compared with the first transplant. In conclusion, the long-term storage of PBSC at − 80°C after uncontrolled-rate freezing is an easy and comparatively inexpensive cryopreservation method that leads to successful haematopoietic recovery even after prolonged storage.
INTRODUCTION
Over the past 20 years, peripheral blood haematopoietic stem cells (PBSC) have been cryopreserved at − 196°C, − 152°C or − 135°C, or − 80°C, reflecting the temperatures of liquid nitrogen, vapour phase nitrogen and mechanical freezers, respectively. To avoid infectious agent contamination through liquid nitrogen in tanks, 1 the most widely adopted storage condition is − 152°C in vapour phase nitrogen. Storage in liquid or gaseous nitrogen requires controlled-rate freezing (CRF), which is time consuming and uses expensive computer-controlled devices. To date, no consensus exists on the optimal PBSC freezing protocol. [2] [3] [4] [5] Successful engraftment with bone marrow stem cells stored at − 80°C after uncontrolled-rate freezing was first described in 1987 by Stiff et al. 6 This simplified procedure was later used successfully at other centres. [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] We recently reported the results of a prospective study that include a large number of autologous PBSCTs performed after freezing and cryopreservation at − 80°C for o6 months. 18 In this study both short-term and long-term haematologic and immunologic recoveries seemed not to differ from recoveries observed after conventional freezing approach. However, although PBSC cryopreservation using liquid nitrogen and controlled-rate freezing is suitable for long-term storage (more than 10 years [19] [20] [21] ), the reliability of long-term PBSC storage at − 80°C is still not clear. Several studies have shown quantitative and qualitative losses in PBSC stored for longer than 6 months, 15, 22 whereas other studies have reported no significant change in post-thawing recovery parameters including cell viability, CD34 + cells, burst forming uniterythroid or colony forming unit-granulocyte macrophage. 5, 23 The short-term haematopoietic reconstitution of PBSC kept at − 80°C was comparable with that observed after storage in liquid nitrogen but was only assessed after storage for 4 months, 6 7 months 8, 15 or up to 23 months. 22 To evaluate the impact of long-term storage on haematopoietic recovery after both uncontrolled-rate freezing and cryopreservation at − 80°C, we combined engraftment clinical data from 666 autologous PBSC transplantations (PBSCTs) performed in two haematology departments, one from France, and one from Belgium.
MATERIALS AND METHODS

Patients and centres
We collected data from 666 autografts performed between 1994 and 2008 with autologous PBSC that had been collected and cryopreserved at − 80°C in a mechanical freezer at two European centres; centre 1 (n = 464), Centre de Biothérapie d'Auvergne, Banque de cellules, CHU Clermont Ferrand, France, and centre 2 (n = 202), Banque de cellules souches, CH Jolimont, Belgium. All the grafts realised with PBSC cryopreserved at − 80°C after uncontrolled-rate freezing were included in the present study. This method was the only available validated method for all PBSC collected 1 at centre 2, whereas centre 1 used both conventional and − 80°C cryopreservation depending on the forecast delay between collection and implantation of the PBSC.
Mobilization and collection of PBSC
Informed consent was obtained from all patients for the autologous transplantation, grafts and data analysis according to French and Belgian regulations and/or Joint Accreditation Committee ISCT-EBMT (JACIE) recommendations. The patients underwent stem cell mobilization stimulated by growth factors or by a combination of chemotherapy and growth factors. Leukapheresis was performed using a Cobe Spectra Cell Separator at each centre (Gambro BCT, Bourg-la-Reine, France or Caridian BCT, Lakewood, CO, USA). If a combination of different collection products was required to obtain the target number of CD34 + cells/kg, the most recent cellular product collection date was used for the calculation of the duration of cryopreservation.
Cryopreservation and transplant of PBSC
The cryopreservation protocols of the PBSC used at both centres were similar, including low dimethyl sulfoxyde (DMSO) concentrations and the same extracellular cryoprotectant human serum albumin (HES) for uncontrolled-rate freezing and storage at − 80°C in mechanical freezers. The final concentrations used at centre 1 were 3.5% DMSO (Braun, Boulogne, France), 1% human serum albumin (HSA) (Octalbine, Lingolsheim, France) and 2.5% hydroxy ethyl starch (HES). The final concentrations used at centre 2 were 6% DMSO (WAK-Chemie Medical, Steinbach/Ts, Germany) and 6% HES (Voluven, Fresenius Kabi, Bad Homburg, Germany).
Cells were transferred into cryocyte bags (Cryocyte, Baxter, Deerfield, IL, USA) that were placed into an aluminium canister and, in a horizontal position, introduced into an empty compartment of a − 80°C mechanical freezer (Thermo, Saint-Herblain, France or New Brunswick Scientific, NJ, USA). The bags were stored at − 80°C in the same freezer until PBSCT. Liquid nitrogen or CO 2 tanks were used as back-up systems to maintain the frozen cells at the predetermined temperature even in the case of power or mechanical failure. Thawed PBSC were not washed before infusion. Cells were thawed in either a 37°C water bath or a warming device (Plasmatherm, Barkey, Germany) and then infused as soon as possible (within 10 min). Various conditioning regimens were used that are reported as 'intensive' (regimens including total body irradiation, carmustin, etoposide, cytarabine, melphalan (BEAM) or BEAM derived) and 'less intensive' (single-agent therapy including high-dose melphalan or other drug combinations).
Haematopoietic recovery
Neutrophil recovery was defined as the first of 3 consecutive days on which polymorphonuclear neutrophils exceeded 0.5 × 10 9 /L. The time to platelet engraftment was defined as the first of 3 days with 20 × 10 9 /L platelets without platelet transfusion.
Sequential transplantation
We analysed the haematopoietic recoveries of 50 pairs of sequential transplantations from the same PBSC mobilization. The aim was to estimate the influence of the storage duration of PBSC on haematopoietic reconstitution, regardless of patient or initial PBSC product characteristics.
Statistical analysis
Statistical analyses were performed independently at both centres (centre 1: s.e.m. software 24 and centre 2: MedCalc v11.1.1.0, MedCalc software BVBA, Mariakerke, Belgium, and GraphPad Prism, version 3.00, San Diego, CA, USA) to confirm results. Descriptive statistics were used to characterize the populations, including the median and range. Univariate analysis was performed using the χ 2 test and/or Fisher's exact test for qualitative analysis and the Kruskal-Wallis and Mann-Whitney tests for quantitative analysis. Correlations were analysed using Spearman's test. Neutrophil and platelet recovery over time were calculated using the Kaplan-Meier survival analysis technique and the log-rank test was used to assess differences between recovery curves. A probability of o0.05 was considered to be statistically significant. Multivariate analysis concerning variables with P o0.1 for neutrophil and platelet recovery was performed using a linear regression model.
RESULTS
Transplant characteristics
We analysed a total of 666 PBSC transplants. The characteristics according to each centre are compared in Table 1 . The median age was lower at centre 1 as 83 paediatric patients were included, whereas only adult patients were treated at centre 2. A larger number of patients with a diagnosis of solid tumours were included from centre 1 (29% versus 7% in centre 2). In addition, the median number of infused CD34 + cells was higher at centre 1, the median storage duration was longer at centre 2 and the use of granulocyte colony stimulating factor after SCT was more frequent at centre 2. At centre 1, growth factors were administered (8) 28 (4) according to delayed haematopoietic reconstitution and were not significantly correlated with the CD34 + cell dose infused (P = 0.96). To investigate the influence of storage duration on haematopoietic reconstitution, we defined three groups of PBSC transplants for this analysis (Table 2 ). In group I (n = 566), group II (n = 40) and group III (n = 60), PBSC were stored for o6 months (median cryopreservation time: 51 days, range: 3-180), from 6 to 12 months (median cryopreservation time: 232 days, range: 186-359) and for more than 12 months (median cryopreservation time: 714 days, range: 399-4148), respectively. The three groups were similar with respect to diagnosis, conditioning regimens and the median CD34 + cell dose. The median age was found to be significantly different (P = 0.008), with more paediatric patients in group II (24% versus 12% and 0% in groups I and III, respectively), whereas more patients were given granulocyte growth factors in groups II and III. The representation of centres 1 and 2 was well balanced in groups I and II, whereas most patients in group III came from centre 2, where granulocyte growth factors use is systematic after autologous transplantation.
Haematopoietic reconstitution
The median number of days required to reach 20 × 10 9 /L platelets was similar at both centres: 12 versus 11 days (P = 0.1), whereas the median time to reach 0.5 × 10 9 /L neutrophils was significantly different (13 versus 11 days), most likely as a result of the routine use of growth factors at centre 2 (Table 3) . No correlation was found between sex, age, conditioning regimens and haematopoietic reconstitution.
The CD34 + cell dose and the use of growth factors were positively correlated with neutrophil recovery. The median time required to reach 0.5 × 10 9 /L neutrophils was 12 (1-43), 11 (7-28) and 11 (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) days in groups I, II and III, respectively. We did not observe any negative impact of storage duration on neutrophil recovery. In contrast, neutrophil reconstitution was faster in groups II and III compared with group I (P o 0.001), whereas no significant difference between groups II and III (P = 0.8) was noted. Similar results were found when neutrophil reconstitution was studied as a function of time, using Kaplan-Meier analysis and logrank test for curve comparison (Figures 1a and b) .
The CD34
+ cell dose and diagnosis were correlated with platelet reconstitution but not with the use of growth factors. Moreover, we observed no influence of storage duration in the three groups on platelet recovery (P = 0.4).
Multivariate analysis confirmed only the centre (P o 0.01) and the infused CD34 + cell dose (P o 0.01) as independent factors affecting neutrophil recovery and only the infused CD34 cells dose (P o 0.001) as the independent factor affecting platelet recovery.
Sequential transplantation with the same PBSC The characteristics of the 50 sequential transplants are illustrated in Table 4 . In the population, 60% were men and 40% were women. The most frequent diagnoses were myeloma (n = 27, 54%) and lymphoma (n = 11, 22%). The median durations of PBSC cryopreservation were 54.1 (range: 7-936) and 213 (range 35-2620) days for the first and second transplantation, respectively. The CD34 + cell doses and conditioning regimens were similar. Despite prolonged cryopreservation, there were no statistically significant differences in either neutrophils (P = 0.09) or platelets (P = 0.22) recovery.
DISCUSSION
The most widespread PBSC cryopreservation technique is controlled-rate freezing and storage in vapour phase nitrogen, which is a time-consuming procedure that requires expensive instruments and heavy structures for liquid nitrogen handling. The two centres in this study used a simplified method for the freezing and cryopreservation of PBSC that was originally described in 1987 by Stiff et al. 6 We adapted Stiff's protocol using lower concentrations of DMSO and adding HES as an extracellular cryoprotectant. 8 Both centres used uncontrolled-rate freezing and long-term cryopreservation of PBSC in − 80°C mechanical freezers. It should be stressed, however, that even if one accepts that products are stable at − 80°C, the safety margin against warming events is inherently reduced compared with ultra low temperature storage. To minimize such risks, all vessels storing human therapy products must have continuous temperature recording and remote alarms to alert staff in case of mechanical failure. In this Long-term cryopreservation of PBSC at − 80°C G Detry et al instance, a separate autonomous backup liquid CO 2 or nitrogen supply is mandatory to allow an adequate response time. Several authors have described the biological characteristics of PBSC stored in − 80°C mechanical freezers. Several studies 15, 22 showed quantitative and functional loss of PBSC stored beyond 6 months, whereas other studies 5, 17, 23, 25, 26 observed no correlation between PBSC storage duration and recovery even 5 years after freezing. Moreover, only few publications have investigated the influence of long-term storage at − 80°C on haematopoietic reconstitution following the transplantation of PBSC. Several others studies, reviewed by Halle et al.,
17 described a total of 256 haematopoietic reconstitutions after autologous PBSC transplantation. The maximum duration of cryopreservation analysed in these studies was 98 weeks and was generally o6 months. Galmes et al. 15, 16 claimed that PBSC cryopreserved in − 80°C mechanical freezers should not be stored for more than 6 months before transplantation, especially if the DMSO concentration is o10%. In addition and in contrast with our freezing technique, HES was not used as an extracellular cryoprotective solution in Galmes'study.
There is some variation in non-CRF practices. For example, two studies 27,28 using HES-free techniques but storing the PBSC in liquid nitrogen vapour demonstrated effective cryopreservation. Moreover, HES is currently unavailable in several countries, and it cannot be inferred from our study that the long-term storage of stem cells in HES-free medium is safe until additional studies are made available. All of these different procedures could simplify and reduce the cost and technical time without the risk of overnight storage before processing.
In this retrospective study we analysed haematopoietic reconstitution of 666 patients receiving transplants after freezing at − 80°C for a median duration of 500 days (range: 3-4148). The engraftment data were obtained from two independent haematology centres. Although both teams used a similar method for PBSC cryopreservation, significant differences were noted between the two cohorts. A lower median age at centre 1 was due to the inclusion of 83 paediatric patients. More patients with solid tumours were treated at centre 1. In contrast to centre 1, growth factors were systematically used at centre 2. A higher dose of CD34 + cells was given to patients at centre 1. Similar to the findings of other studies on uncontrolled-rate freezing and storage at − 80°C 9, 10, 12, [15] [16] [17] [18] as well as controlled-rate freezing and storage in nitrogen, [29] [30] [31] we observed that the infused CD34 + cell dose influenced platelet and neutrophil reconstitution. Other factors that had an impact on early haematopoietic reconstitution, 16, 18 such as diagnosis (for platelets) and the administration of growth factors after transplantation (for neutrophils), were confirmed in our study.
Three groups of PBSC transplants were delineated according to the duration of PBSC cryopreservation at − 80°C. Groups I, II and III were characterized by PBSC storage for o 6 months, 6-12 months and >12 months, respectively. Patients from group II were younger and more patients from group III were given growth factors post transplantation. We observed a statistically significant difference in neutrophil reconstitution between groups I and II and groups I and III with a longer neutrophil recovery time in patients from group I. This paradoxical observation could have resulted from a higher proportion of patients from centre 2 in groups II and III, as these patients benefited from a systematic administration of growth factors. Therefore, a sub-analysis comparing the neutrophil recovery in groups I, II and III who were given growth factors and in groups I, II and III who were not given growth factors was performed (data not shown). In the patients who were not given growth factors, no differences were observed based on storage duration. Platelet reconstitution was found to be similar in the three groups.
Of note, the storage duration had no independent impact on neutrophil recovery in a multivariate analysis.
In an attempt to minimize patient and graft heterogeneity, we analysed 50 autologous tandem transplants using PBSC collected during the same procedure. We did not observe any significant differences in haematopoietic reconstitution between the first and the second transplants despite the use of PBSC with different storage durations.
In conclusion, our study shows that PBSC subjected to uncontrolled-rate freezing and cryopreservation with 5% DMSO combined with HES at − 80°C supports haematopoietic reconstitution comparable to that of controlled-rate freezing and liquid nitrogen vapour-cryopreserved grafts, even after an extended period of storage. This finding held true at two independent centres using similar freezing and storage techniques but distinct clinical routines in different populations. The lower costs of and basic equipment required for this technique could allow for more widespread use of cryopreserved PBSC, especially in countries with limited financial resources. Long-term cryopreservation of PBSC at − 80°C G Detry et al
